查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1882969

腦膜炎雙球菌疫苗市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2024-2032 年）

Meningococcal Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 161 Pages | 商品交期: 請詢問到貨日

價格

腦膜炎雙球菌疫苗市場成長驅動因子

受疫苗可預防的腦膜炎球菌疾病病例數量不斷增加以及全球疫苗接種工作不斷擴大的推動，全球腦膜炎球菌疫苗市場持續顯著增長。根據 2024 年的報告，2024 年腦膜炎雙球菌疫苗市場規模達到 35.4 億美元。預計到 2025 年，該市場規模將成長至 38.1 億美元，到 2032 年將達到 73.4 億美元，2025 年至 2032 年的複合年增長率 (CAGR) 為 9.8%。北美地區在 2024 年以 57.34% 的市佔率引領全球市場，這反映了該地區較高的疫苗接種率和已獲批准疫苗的大規模應用。

腦膜炎雙球菌感染（包括腦膜炎、敗血症和肺炎）是由腦膜炎奈瑟菌引起的。該菌有12种血清型，其中6種（A、B、C、W、X和Y）是流行的主要原因。細菌性腦膜炎仍然是一種危及生命的疾病，如果不及時治療，往往會導致嚴重的神經損傷甚至死亡。腦膜炎雙球菌感染的日益流行，加上人們對該疾病認識的提高以及疫苗研發方面的國際合作，持續推動著疫苗市場的顯著成長。例如，2024年4月，印度血清研究所與牛津大學合作開發了一種基於嵌合蛋白的B群腦膜炎雙球菌疫苗，擴大了未來疫苗研發的潛力。

市場動態

推動因素

細菌性腦膜炎雙球菌感染的增加顯著推動了疫苗的需求。根據世界衛生組織的數據，六分之一的細菌性腦膜炎患者會死亡，五分之一的患者會遭受長期併發症，例如腦損傷或截肢。 2023年，美國報告了438例腦膜炎球菌疾病病例，這是過去十年來的最高發生率，凸顯了疫苗接種計畫的緊迫性。這種疾病的上升趨勢正在推動對腦膜炎雙球菌疫苗（包括常規疫苗和緊急疫苗）的需求激增。

限制因子

結合疫苗的高成本是市場面臨的主要阻礙因素。生產流程複雜、多組分配方以及冷鏈儲存要求都推高了價格。根據美國疾病管制與預防中心（CDC）發布的疫苗價格表（2025年6月），Penbrayer疫苗每瓶售價230.75美元，Menquadfi疫苗10劑裝售價171.97美元。這可能會延緩低收入地區（缺乏醫療保險）的疫苗普及。

機會

全球疫苗接種計畫蘊藏著巨大的成長機會。世界衛生組織（世衛組織）的 "2030年終結腦膜炎" 路線圖強調，應擴大免疫規劃，並使用價格合理的疫苗，包括Men5CV疫苗。 2025年4月，世衛組織發布了首個關於腦膜炎診斷、治療和長期照護的全球指南，顯著加強了全球應對疫情的準備。

挑戰

冷鏈物流仍然是一項重大挑戰，尤其是在資源匱乏的地區。根據英國衛生安全署2023年的報告，可避免的疫苗浪費造成的損失高達330萬美元，而不可避免的冷鏈中斷造成的損失則高達370萬美元。這些損失正日益加劇公共衛生預算的壓力。

市場區隔亮點

2024年，重組疫苗、結合疫苗和次單位疫苗佔市場主導地位。這得歸功於結合疫苗的廣泛應用以及新產品的推出，例如葛蘭素史克（GSK）的單劑量Menveo疫苗於2024年11月獲批。此外，由於多個國家廣泛推行學校疫苗接種建議，MenACWY疫苗在疫苗類型中佔領先地位。

2024年，兒科疫苗的需求量最高，這主要得益於一些疫苗適應症的擴展，例如賽諾菲（Sanofi）的Menquadfi疫苗獲批用於6週至23個月齡的兒童（於2025年5月獲準）。

由於大規模的國家免疫規劃，政府機構在2024年成為主要的疫苗通路。例如，在 Gavi 的支持下，尼日利亞於 2024 年 4 月成為首個引入 Men5CV 疫苗的國家。

區域展望

北美仍將是最大的區域市場，2024 年市場規模將達到 20.3 億美元，這主要得益於腦膜炎球菌疾病 (IMD) 病例的增加以及強大的公共衛生基礎設施。 2024年6月，多倫多公共衛生局報告了13例侵襲性腦膜炎球菌疾病（IMD）病例，這是自2002年以來的最高數字。

預計亞太地區將在2024年佔第二大佔有率，並在2032年之前保持最快的成長速度，這主要得益於疫苗的引入，例如印度血清研究所的MenFive疫苗，該疫苗於2023年7月獲得世衛組織預認證。歐洲持續受益於較高的常規免疫接種覆蓋率，2022-2023年英格蘭兒童的B群腦膜炎雙球菌疫苗接種覆蓋率達91%。

拉丁美洲和中東/非洲地區仍然是成長型市場，2021年至2023年間，發病率從每10萬人0.05例上升至0.18例，尤其是在腦膜炎帶地區。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 市場機遇
  • 市場趨勢

第四章：主要見解

  • 主要國家和地區的監管情況
  • 主要國家和地區的疫苗接種覆蓋率
  • 主要國家和地區的政府腦膜炎疫苗接種計劃
  • 腦膜炎雙球菌疫苗的技術進步
  • 主要產業趨勢（併購、合作、新產品發表）等等）

第五章：全球腦膜炎雙球菌疫苗市場分析、洞察與預測（2019-2032）

  • 市場分析、洞察與預測 - 依技術分類
    • 重組/結合/次單位疫苗
    • 滅活​​疫苗
    • 其他
  • 市場分析、洞察與預測 - 依類型分類
    • MenACWY疫苗
    • MenB疫苗
    • MenABCWY疫苗
    • 其他
  • 市場分析、洞察與預測 - 依年齡組分類
    • 兒童
    • 成人
  • 市場分析、洞察與預測 - 依銷售管道分類
    • 醫院和零售藥局
    • 政府供應商
    • 其他
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美腦膜炎雙球菌疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲腦膜炎雙球菌疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 德國
    • 美國王國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區腦膜炎雙球菌疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲腦膜炎雙球菌疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區美國

第十章：中東和非洲腦膜炎雙球菌疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
    • 葛蘭素史克 (GSK plc)
    • 賽諾菲 (Sanofi)
    • 默克公司 (Merck & Co., Inc.)
    • 印度血清研究所 (Serum Institute of India Pvt.)有限公司
    • 諾華公司
    • 華生生技有限公司
    • 華蘭生物疫苗股份有限公司
    • 生物農場
    • 亞洲生物網。
Product Code: FBI113758

Growth Factors of meningococcal vaccines Market

The global meningococcal vaccines market continues to advance significantly, driven by rising cases of vaccine-preventable meningococcal diseases and increasing global immunization efforts. According to the 2024 report, the meningococcal vaccines market size reached USD 3.54 billion in 2024. The market is projected to increase to USD 3.81 billion in 2025 and rise further to USD 7.34 billion by 2032, expanding at a CAGR of 9.8% between 2025 and 2032. In 2024, North America dominated the global market with a 57.34% share, indicating strong vaccination coverage and large-scale adoption of approved vaccines.

Meningococcal diseases-including meningitis, sepsis, and pneumonia-are caused by Neisseria meningitidis. Although 12 serogroups exist, six (A, B, C, W, X, and Y) are responsible for major epidemics. Bacterial meningitis remains life-threatening, often causing severe neurological damage or death if not treated promptly. The rising burden of meningococcal infections, coupled with increasing awareness and global collaborations for vaccine development, continues to drive substantial market growth. For example, in April 2024, the Serum Institute of India partnered with the University of Oxford to develop a chimeric protein-based Men-B vaccine, expanding future vaccine possibilities.

Market Dynamics

Drivers

The increasing number of bacterial meningococcal infections is significantly boosting vaccine demand. WHO reports indicate that 1 in 6 bacterial meningitis patients die, and 1 in 5 suffer long-term complications such as brain damage or amputations. In 2023, the U.S. reported 438 cases of meningococcal disease, the highest incidence in a decade, highlighting the urgent need for immunization programs. Such rising disease patterns support fast-growing demand for both routine and emergency meningococcal vaccinations.

Restraints

A key market restraint is the high cost of conjugate vaccines. Manufacturing complexity, multi-component formulations, and cold-chain storage requirements contribute to elevated pricing. According to the CDC Vaccine Price List (June 2025), Penbraya costs USD 230.75 per vial, while MenQuadfi costs USD 171.97 for a 10-pack dose-prices that may slow adoption in low-income regions without insurance coverage.

Opportunities

Global vaccination initiatives present strong growth opportunities. WHO's "Defeating Meningitis by 2030" roadmap emphasizes expanded immunization programs using affordable vaccines, including Men5CV. In April 2025, WHO released the first global guidelines for meningitis diagnosis, treatment, and long-term care, significantly strengthening global preparedness.

Challenges

Cold-chain logistics remain a major challenge, especially in low-resource settings. As per the 2023 U.K. Health Security Agency report, vaccine wastage due to avoidable reasons cost USD 3.3 million, while unavoidable cold-chain failures cost USD 3.7 million. Such losses increase pressure on public health budgets.

Market Segmentation Highlights

Recombinant/conjugate/subunit vaccines dominated in 2024, supported by widespread availability of conjugate vaccines and new product approvals such as GSK's single-vial Menveo in November 2024. The MenACWY segment led by type due to broad, school-based immunization recommendations across multiple countries.

Pediatric vaccines generated the highest demand in 2024, strengthened by expansions such as Sanofi's MenQuadfi pediatric indication (May 2025) for infants aged 6 weeks to 23 months.

Government suppliers represented the leading distribution channel in 2024 because of large-scale national immunization programs. For example, Nigeria became the first country to introduce Men5CV in April 2024, supported by Gavi.

Regional Outlook

North America remained the dominant region with a 2024 market size of USD 2.03 billion, driven by rising IMD cases and strong public health infrastructure. In June 2024, Toronto Public Health reported 13 IMD cases, the highest since 2002.

Asia Pacific held the second-largest share in 2024 and is projected to grow fastest through 2032, supported by WHO-prequalified vaccines such as Serum Institute's MenFive in July 2023. Europe continues to benefit from high routine immunization coverage, including 91% MenB vaccination-rate among children in England in 2022-23.

Latin America and Middle East & Africa remain growing markets, especially in the meningitis belt, where incidence rose from 0.05 to 0.18 per 100,000 between 2021 and 2023.

Conclusion

With global market value rising from USD 3.54 billion in 2024 to USD 7.34 billion by 2032, the meningococcal vaccines market is set for substantial long-term expansion. Strong R&D efforts, supportive government initiatives, and increased disease awareness will continue to drive growth through 2032.

Segmentation By Technology

  • Recombinant/Conjugate/Subunit
  • Inactivated
  • Others

By Type

  • MenACWY Vaccines
  • MenB Vaccines
  • MenABCWY Vaccines
  • Others

By Age Group

  • Pediatric
  • Adults

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Geography

  • North America (By Technology, Type, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Vaccination Coverage- By Key Countries/ Regions
  • 4.3. Government Immunization Programs for Meningitis, By Key Countries/ Regions
  • 4.4. Technological Advancements in Meningococcal Vaccines Market
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Technology
    • 5.1.1. Recombinant/Conjugate/Subunit
    • 5.1.2. Inactivated
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. MenACWY Vaccines
    • 5.2.2. MenB Vaccines
    • 5.2.3. MenABCWY Vaccines
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adults
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Technology
    • 6.1.1. Recombinant/Conjugate/Subunit
    • 6.1.2. Inactivated
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. MenACWY Vaccines
    • 6.2.2. MenB Vaccines
    • 6.2.3. MenABCWY Vaccines
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adults
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Technology
    • 7.1.1. Recombinant/Conjugate/Subunit
    • 7.1.2. Inactivated
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. MenACWY Vaccines
    • 7.2.2. MenB Vaccines
    • 7.2.3. MenABCWY Vaccines
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adults
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Technology
    • 8.1.1. Recombinant/Conjugate/Subunit
    • 8.1.2. Inactivated
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. MenACWY Vaccines
    • 8.2.2. MenB Vaccines
    • 8.2.3. MenABCWY Vaccines
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adults
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Technology
    • 9.1.1. Recombinant/Conjugate/Subunit
    • 9.1.2. Inactivated
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. MenACWY Vaccines
    • 9.2.2. MenB Vaccines
    • 9.2.3. MenABCWY Vaccines
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adults
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Technology
    • 10.1.1. Recombinant/Conjugate/Subunit
    • 10.1.2. Inactivated
    • 10.1.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By Type
    • 10.2.1. MenACWY Vaccines
    • 10.2.2. MenB Vaccines
    • 10.2.3. MenABCWY Vaccines
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adults
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Serum Institute of India Pvt. Ltd.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Novartis AG
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Walvax Biotechnology Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Hualan Biological Vaccine Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Bio Farma
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. BioNet-Asia.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2019-2032
  • Table 2: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 3: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2019-2032
  • Table 4: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 5: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Region, 2019-2032
  • Table 6: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2019-2032
  • Table 7: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 8: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2019-2032
  • Table 9: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 10: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2019-2032
  • Table 12: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 13: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2019-2032
  • Table 14: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 15: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2019-2032
  • Table 17: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 18: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2019-2032
  • Table 19: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 20: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2019-2032
  • Table 22: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 23: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2019-2032
  • Table 24: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 25: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 26: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2019-2032
  • Table 27: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 28: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2019-2032
  • Table 29: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 30: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Meningococcal Vaccines Market Revenue Breakdown (USD billion, %) By Region, 2024 & 2032
  • Figure 2: Global Meningococcal Vaccines Market Value Share (%), By Technology, 2024 & 2032
  • Figure 3: Global Meningococcal Vaccines Market Value Share (%), By Type, 2024 & 2032
  • Figure 4: Global Meningococcal Vaccines Market Value Share (%), By Age Group, 2024 & 2032
  • Figure 5: Global Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2024 & 2032
  • Figure 6: Global Meningococcal Vaccines Market Value Share (%), By Region, 2024 & 2032
  • Figure 7: North America Meningococcal Vaccines Market Value (USD billion), By Technology, 2024 & 2032
  • Figure 8: North America Meningococcal Vaccines Market Value Share (%), By Technology, 2024
  • Figure 9: North America Meningococcal Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 10: North America Meningococcal Vaccines Market Value Share (%), By Type, 2024
  • Figure 11: North America Meningococcal Vaccines Market Value (USD billion), By Age Group, 2024 & 2032
  • Figure 12: North America Meningococcal Vaccines Market Value Share (%), By Age Group, 2024
  • Figure 13: North America Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 14: North America Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 15: North America Meningococcal Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 16: North America Meningococcal Vaccines Market Value Share (%), By Country, 2024
  • Figure 17: Europe Meningococcal Vaccines Market Value (USD billion), By Technology, 2024 & 2032
  • Figure 18: Europe Meningococcal Vaccines Market Value Share (%), By Technology, 2024
  • Figure 19: Europe Meningococcal Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 20: Europe Meningococcal Vaccines Market Value Share (%), By Type, 2024
  • Figure 21: Europe Meningococcal Vaccines Market Value (USD billion), By Age Group, 2024 & 2032
  • Figure 22: Europe Meningococcal Vaccines Market Value Share (%), By Age Group, 2024
  • Figure 23: Europe Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 24: Europe Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 25: Europe Meningococcal Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 26: Europe Meningococcal Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 27: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Technology, 2024 & 2032
  • Figure 28: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Technology, 2024
  • Figure 29: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 30: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Type, 2024
  • Figure 31: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Age Group, 2024 & 2032
  • Figure 32: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Age Group, 2024
  • Figure 33: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 35: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 36: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 37: Latin America Meningococcal Vaccines Market Value (USD billion), By Technology, 2024 & 2032
  • Figure 38: Latin America Meningococcal Vaccines Market Value Share (%), By Technology, 2024
  • Figure 39: Latin America Meningococcal Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 40: Latin America Meningococcal Vaccines Market Value Share (%), By Type, 2024
  • Figure 41: Latin America Meningococcal Vaccines Market Value (USD billion), By Age Group, 2024 & 2032
  • Figure 42: Latin America Meningococcal Vaccines Market Value Share (%), By Age Group, 2024
  • Figure 43: Latin America Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 45: Latin America Meningococcal Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 46: Latin America Meningococcal Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 47: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Technology, 2024 & 2032
  • Figure 48: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Technology, 2024
  • Figure 49: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 50: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Type, 2024
  • Figure 51: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Age Group, 2024 & 2032
  • Figure 52: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Age Group, 2024
  • Figure 53: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 55: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 56: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 57: Global Meningococcal Vaccines Market Share (%), By Company, 2024